OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company specializing in antibody discovery, providing partnered drug developers access to transgenic animal platforms engineered to generate fully human therapeutic antibodies. The company went public in October 2022 through a merger with Avista Public Acquisition Corp. II, a healthcare-focused blank-check vehicle sponsored by Avista Capital Partners that completed its IPO in 2021. OmniAb was concurrently spun off from Ligand Pharmaceuticals as part of the de-SPAC transaction. The company filed an 8-K with the SEC on June 18, 2025, continuing its profile as a post-merger Nasdaq-listed issuer in the life sciences sector. Sign up at SpacDesk for full filing history, deal analytics, and SPAC intelligence on OmniAb and hundreds of completed transactions.